Estrofem | 65296-29-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: Estrofem
• 英文别名: (8R,9S,13S,14S,17S)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol;(8R,9S,13S,14S,16R,17R)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,16,17-triol
• CAS: 65296-29-9
• 化学式: C36H48O5
• 分子量: 560.8
• InChiKey: YUSCRGFYKCAQHE-HQFNMCNFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.19
• 重原子数：
  41
• 可旋转键数：
  0
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  101
• 氢给体数：
  5
• 氢受体数：
  5

文献信息

• Zusammensetzung zur Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
  申请人：Wyeth

  公开号：EP1935423A3

  公开（公告）日：2010-01-06

  Verwerdung einer Kombination, aus einem einzelnen·Gestagen, ausgewählt aus der aus Progesteron, Chlormadinonacetat, Norethistronacetat, Cyproteronacetat, Desogestrel, Levonor-gestrel, Antigestagenen, Horinonanalogen mit Gestagen- oder Antigestagenwirkung und Hormonverbindungen, die mindestens ein Gestagen nach Einnahme rasch abspalten, bestehenden Gruppe, und eines einzelnen Estrogens, ausgewahlt aus der aus synthetischem Estrogen, namlich Ethinylestradiol mit einer taglichen Dosis von 1 - 20 µg, Mestranol oder einer Hormonverbindung, die mindestens ein synthetisches Estrogen nach Einnahme rasch abspaltet und biogenen Estragenen, nämlich Estradiol Estriol, Estron, Estran oder einer Hormonverbindung, die mindestens ein biogenes Eströgen nach Einnahme rasch abspaltet bestehen-den Gruppe, als alleinigen hormonellen Wirkstoffen zur Herstellung eines Mittels zur und/oder Prophylaxe von Tumoren der Brustdrüsen durch ununterbrochene orale, transdermale oder Depot-Verabreichung.

  使用从黄体酮、醋酸氯地孕酮、醋酸炔诺酮、醋酸环丙孕酮、去氧孕酮、左旋炔诺酮、抗雌激素、具有孕激素或抗雌激素作用的炔诺酮类似物和激素化合物组成的组中选出的单一孕激素组合、一种雌激素，选自合成雌激素（即炔雌醇，日剂量为 1 - 20 微克）或一种激素复合物、雌二醇或摄入后能迅速分解至少一种合成雌激素的激素化合物，以及生物雌激素，即雌二醇、雌三醇、雌酮、雌三醇或摄入后能迅速分解至少一种生物雌激素的激素化合物，作为唯一的激素活性成分，用于制备连续口服、透皮或去势给药的乳腺肿瘤治疗剂和/或预防剂。
• Method and system for detecting aromatic compounds
  申请人：Applin Biotech Co. Ltd.

  公开号：US11262336B2

  公开（公告）日：2022-03-01

  A method for analyzing aromatic compounds, and a reagent kit for LC-MS analysis of aromatic compounds. The method includes preparing a diazonium reagent, contacting aromatic compounds in a sample with the diazonium reagent to form an analyte; and measuring an amount or ratio of the analyte. The reagent kit includes a diazonium reagent, wherein the diazonium reagent includes (i) a diazonium salt that contains a diazonium ion; (ii) an amine and nitrous acid; and/or (iii) a nitrite and an acid.

  一种分析芳香族化合物的方法和一种用于 LC-MS 分析芳香族化合物的试剂盒。该方法包括制备重氮试剂，将样品中的芳香族化合物与重氮试剂接触以形成分析物；以及测量分析物的量或比率。试剂盒包括重氮试剂，其中重氮试剂包括 (i) 含有重氮离子的重氮盐；(ii) 氨基和亚硝酸；和/或 (iii) 亚硝酸盐和酸。
• FILMFÖRMIGES, ORAL ZU VERABREICHENDES ARZNEIMITTEL, ENTHALTEND ESTRIOL
  申请人：HF ARZNEIMITTELFORSCHUNG GmbH

  公开号：EP1761242A2

  公开（公告）日：2007-03-14
• TOPICAL COMPOSITIONS FOR ANTI-AGING AND METHODS OF USING SAME
  申请人：McClellan Stephanie N.

  公开号：US20100272833A1

  公开（公告）日：2010-10-28

  A pharmaceutical composition for treatment of skin aging including a pharmaceutically effective amount of estriol; a pharmaceutically effective amount of estradiol; a pharmaceutically effective amount of hyaluronic acid; a pharmaceutically effective amount of green tea extract; and a pharmaceutically acceptable carrier is provided. In some embodiments, the composition further includes ascorbic acid, date palm extract, or a combination thereof. Also disclosed is a method for treating symptoms of skin aging and photoaging by administering a pharmaceutical composition having estriol, estradiol, hyaluronic acid, green tea extract, a pharmaceutically acceptable carrier and optionally, ascorbic acid and date palm extract. A method of promoting urogenital function is likewise provided wherein a pharmaceutical composition having estriol, estradiol, hyaluronic acid, and green tea extract is applied intravaginally.
• Topical compositions for anti-aging and methods of using same
  申请人：McClellan Stephanie N.

  公开号：US20110003020A1

  公开（公告）日：2011-01-06

  A pharmaceutical composition for treatment of skin aging including a pharmaceutically effective amount of estriol; a pharmaceutically effective amount of estradiol; a pharmaceutically effective amount of hyaluronic acid; a pharmaceutically effective amount of green tea extract; and a pharmaceutically acceptable carrier is provided. In some embodiments, the composition further includes ascorbic acid, date palm extract, or a combination thereof. Also disclosed is a method for treating symptoms of skin aging and photoaging by administering a pharmaceutical composition having estriol, estradiol, hyaluronic acid, green tea extract, a pharmaceutically acceptable carrier and optionally, ascorbic acid and date palm extract. A method of promoting urogenital function is likewise provided wherein a pharmaceutical composition having estriol, estradiol, hyaluronic acid, and green tea extract is applied intravaginally.